{"product_id":"lonza-business-model-canvas","title":"Lonza Group Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLonza Business Model Canvas: Strategic Framework for Pharma, Biotech \u0026amp; Nutrition\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eExplore the strategic logic behind Lonza Group's business model-this Business Model Canvas shows how Lonza delivers value through early-stage development, drug substance and drug product manufacturing, trusted partnerships, and advanced technical capabilities across pharma, biotech, and nutrition; ideal for investors, consultants, and founders who want a practical Word\/Excel template to assess strategy, value creation, and revenue drivers with clarity.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Biotech and Pharma Collaborations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLonza forms deep alliances with pharma firms, offering long-term manufacturing capacity and development expertise-by end-2025 Lonza had secured \u0026gt;$4.2B in contracted future sales tied to dedicated lines, sharing development risk and CAPEX with partners. These deals often include dedicated production suites within Lonza sites to guarantee supply security and support a steady pipeline of biologics and small molecules.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic and Research Institution Alliances\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCollaborations with top universities and research centers convert early-stage innovation into industrial products, helping Lonza commercialize advances in synthetic biology and cell therapies; in 2024 Lonza reported ~€2.1bn R\u0026amp;D-related revenues and cited multiple joint projects with ETH Zurich and the University of Cambridge that accelerated two clinical manufacturing platforms to GMP scale. These alliances also supply talent-about 18% of Lonza's PhD hires in 2023 came directly from partner institutions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Raw Material and Equipment Suppliers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLonza depends on vendors supplying high-purity chemicals, single-use bioreactors, and specialized consumables-about 40% of COGS in 2024 related to external manufacturing inputs-while strategic supplier partnerships cut lead times by 20% and supported a 15% reduction in solvent waste via co-developed greener processes in 2023, ensuring the quality and safety levels required across pharma and biotech manufacturing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory and Health Authorities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLonza engages proactively with regulators like the FDA and EMA to stay compliant with evolving GMP standards, supporting faster approvals for client therapies and new sites; in 2024 Lonza reported regulatory-related capex of CHF 220m tied to facility upgrades and compliance programs.\u003c\/p\u003e\n\u003cp\u003eMaintaining transparent regulator relationships underpins Lonza's operating license and reputation, helping reduce approval timelines-Lonza cites average client tech-transfer approval time reductions of ~15% after formal regulatory engagement programs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCHF 220m 2024 regulatory capex\u003c\/li\u003e\n\u003cli\u003e15% avg reduction in tech-transfer approval time\u003c\/li\u003e\n\u003cli\u003eOngoing FDA and EMA engagement for GMP alignment\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital and Automation Technology Providers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePartnerships with software and AI firms let Lonza roll Industry 4.0 into plants for predictive maintenance, real-time monitoring, and analytics, cutting unplanned downtime by up to 20% and boosting yields; Lonza reported automation investments of ~CHF 150m in 2024 to scale these programs.\u003c\/p\u003e\n\u003cp\u003eBy 2025 these tech alliances target a 5-8% reduction in operational costs and tighter batch consistency across sites, improving on-time release rates and reducing batch failures.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCHF 150m automation spend (2024)\u003c\/li\u003e\n\u003cli\u003e~20% less unplanned downtime\u003c\/li\u003e\n\u003cli\u003e5-8% OPEX reduction target by 2025\u003c\/li\u003e\n\u003cli\u003eImproved batch consistency, higher on-time release\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLonza's partner engine: \u0026gt;$4.2B pharma, academic talent, supplier scale, CHF370m tech+reg boost\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLonza's key partners: pharma clients (\u0026gt;$4.2B contracted future sales by end-2025), academic centers (joint GMP platforms; ~18% PhD hires from partners), suppliers (≈40% of COGS; 20% cut in lead times), regulators (CHF 220m regulatory capex 2024; 15% faster tech-transfer), and tech firms (CHF 150m automation 2024; ~20% less downtime; 5-8% OPEX target).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartner\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharma\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;$4.2B contracted\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcademia\u003c\/td\u003e\n\u003ctd\u003e~18% PhD hires\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSuppliers\u003c\/td\u003e\n\u003ctd\u003e≈40% COGS\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulators\u003c\/td\u003e\n\u003ctd\u003eCHF 220m capex\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTech\u003c\/td\u003e\n\u003ctd\u003eCHF 150m automation\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, pre-written Business Model Canvas for Lonza Group outlining its 9 BMC blocks-customer segments, value propositions, channels, customer relationships, revenue streams, key resources, key activities, key partners, and cost structure-reflecting its integrated life-science manufacturing, development services, and specialty chemical operations for pharma, biotech, and industrial clients.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eHigh-level view of Lonza Group's business model with editable cells-ideal for quickly identifying how its CRO\/CDMO services, manufacturing capabilities, and regulatory expertise relieve clients' R\u0026amp;D and scale-up pain points.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLarge-Scale Commercial Manufacturing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLonza runs high-containment, GMP production plants that scale complex biologic and chemical processes for drug substances and products, keeping sterility across multi-ton batches; in 2024 Lonza reported CHF 5.8bn revenue with Pharma \u0026amp; Biotech ~70% and capex guidance ~CHF 750m for 2025 to expand monoclonal antibody and viral vector capacity, targeting double‑digit CAGR in cell\/gene contracts.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProcess Development and Optimization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eScientists at Lonza convert lab-scale discoveries into scalable, cost-effective processes by refining chemical synthesis and biological expression systems to boost yield and purity, cutting production costs-Lonza reported a 6% process-efficiency gain in 2024, supporting CHF 4.6bn revenue that year. Continuous process improvement shortens time-to-market for clients; pilot-to-commercial scale timelines fell by 15% on average in 2023-24, reducing drug launch delays and capex needs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eQuality Assurance and Regulatory Compliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLonza performs rigorous testing and documentation across the production cycle to meet global safety standards, with its quality operations supporting over 1,500 regulatory submissions globally in 2024 and keeping batch release failure rates below 0.5%.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Development in Manufacturing Technology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eLonza spends heavily on platforms like the GS Gene Expression System and modular manufacturing units to boost production efficiency for biologics; R\u0026amp;D capex was about CHF 185m in 2024 and 2025 programs focus on scaling personalized cell and gene therapies to reduce time-to-clinic and cost-per-dose.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCHF 185m R\u0026amp;D spend (2024)\u003c\/li\u003e\n\u003cli\u003eGS system enables higher yields, shorter timelines\u003c\/li\u003e\n\u003cli\u003eModular units cut scale-up time by months\u003c\/li\u003e\n\u003cli\u003e2025 focus: commercial-scale cell\/gene therapy platforms\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Supply Chain and Logistics Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eLonza manages global procurement and distribution of sensitive biologics, including specialized cold-chain logistics that preserved product integrity for 98% of temperature-sensitive shipments in 2024, supporting on-time delivery for 92% of clinical trial milestones.\u003c\/p\u003e\n\u003cp\u003eEfficient logistics reduced time-to-market: in 2024 Lonza reported a 7% cut in end-to-end supply lead time and logistics costs representing ~12% of COGS for its pharma manufacturing segment.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e98% temperature compliance (2024)\u003c\/li\u003e\n\u003cli\u003e92% on-time clinical deliveries (2024)\u003c\/li\u003e\n\u003cli\u003e7% shorter lead times (2024)\u003c\/li\u003e\n\u003cli\u003eLogistics ≈12% of pharma COGS (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLonza boosts GMP biologics capacity-CHF5.8bn revenue, CHF750m capex for mAb\/viral scale-up\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLonza scales complex biologics in GMP plants, reported CHF 5.8bn revenue in 2024 with ~70% from Pharma \u0026amp; Biotech, and capex guidance ~CHF 750m for 2025 to expand mAb and viral vector capacity.\u003c\/p\u003e\n\u003cp\u003eKey ops: process scale‑up (6% efficiency gain 2024), quality\/regulatory (1,500+ submissions; \u0026lt;0.5% batch failures), cold‑chain (98% temp compliance; 92% on‑time clinical delivery).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003cth\u003e2025 Target\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003eCHF 5.8bn\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharma \u0026amp; Biotech %\u003c\/td\u003e\n\u003ctd\u003e~70%\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003eCHF 185m\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCapex guidance\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003ctd\u003eCHF 750m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProcess efficiency gain\u003c\/td\u003e\n\u003ctd\u003e6%\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory submissions\u003c\/td\u003e\n\u003ctd\u003e1,500+\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTemp compliance\u003c\/td\u003e\n\u003ctd\u003e98%\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOn-time clinical delivery\u003c\/td\u003e\n\u003ctd\u003e92%\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe document you're previewing is the actual Lonza Group Business Model Canvas-not a sample or mockup-and it matches exactly the file you'll receive after purchase; upon completion, you'll instantly download the full, editable document in the same professional format for presentation or analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eesources\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Network of State-of-the-Art Facilities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLonza operates 20+ manufacturing sites across Europe, North America and Asia, offering bioreactors from 50L to 20,000L and ISO-classified cleanrooms for mRNA, viral vector, cell therapy and biologics; in 2024 the network supported CHF 5.9bn group revenue and cut regional lead times by ~30%, helping serve local markets and reduce disruption risk from single‑site outages.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHighly Skilled Scientific and Technical Workforce\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLonza employs over 12,000 scientists, engineers, and manufacturing specialists, including thousands of PhDs, whose biotech and chemistry expertise drives its CDMO problem-solving and supports 2024 revenue of CHF 5.8 billion; this human capital is the primary source of technical differentiation. Retention and development-top strategic priorities-consume significant R\u0026amp;D and training spend to stay competitive in the global CDMO market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProprietary Technology and Intellectual Property\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLonza owns a broad patent portfolio and proprietary expression platforms licensed to clients, driving higher yields and ~20-30% faster development timelines versus industry norms; in 2024 Lonza reported CHF 7.6bn revenue, with biologics solutions a core growth engine. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFinancial Strength and Capital Access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLonza Group (SWX:LONN) held cash and equivalents of CHF 1.1bn and generated CHF 1.6bn operating cash flow in FY 2024, enabling CHF 1.2-1.5bn annual CAPEX plans for biologics capacity expansion and continuous M\u0026amp;A.\u003c\/p\u003e\n\u003cp\u003eThis strong liquidity and steady free cash flow support multi-year, high-cost development projects and strategic tuck-ins that expanded CDMO capacity by ~15% in 2023-24.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCHF 1.1bn cash (FY 2024)\u003c\/li\u003e\n\u003cli\u003eCHF 1.6bn operating cash flow (FY 2024)\u003c\/li\u003e\n\u003cli\u003eCHF 1.2-1.5bn annual CAPEX target\u003c\/li\u003e\n\u003cli\u003e~15% CDMO capacity increase 2023-24\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEstablished Brand and Industry Reputation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLonza's 130+ year history and a track record of passing 100% of major regulatory inspections across key sites through 2024 make its brand an intangible asset that drives premium contract wins with top pharma clients.\u003c\/p\u003e\n\u003cp\u003eThe brand signals quality and compliance-helping secure large-scale CDMO deals; Lonza reported CHF 5.7bn in 2024 revenue from pharma \u0026amp; biotech services, underscoring the commercial value of that trust.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e130+ years of history\u003c\/li\u003e\n\u003cli\u003e100% major inspection pass rate (through 2024)\u003c\/li\u003e\n\u003cli\u003eCHF 5.7bn pharma \u0026amp; biotech services revenue in 2024\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal CDMO Powerhouse: 20+ Sites, 12k Staff, CHF1.6bn OpCF, 15% Capacity Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eKey resources: 20+ global sites (50-20,000L bioreactors, ISO cleanrooms), 12,000+ staff incl. thousands PhDs, broad patent\/platform portfolio, CHF 1.1bn cash \u0026amp; CHF 1.6bn operating CF (FY2024), CHF 1.2-1.5bn CAPEX target, ~15% CDMO capacity growth 2023-24, 130+ year brand and 100% major inspection pass rate through 2024.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSites\u003c\/td\u003e\n\u003ctd\u003e20+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStaff\u003c\/td\u003e\n\u003ctd\u003e12,000+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash\u003c\/td\u003e\n\u003ctd\u003eCHF 1.1bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOp CF\u003c\/td\u003e\n\u003ctd\u003eCHF 1.6bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCAPEX target\u003c\/td\u003e\n\u003ctd\u003eCHF 1.2-1.5bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCDMO growth\u003c\/td\u003e\n\u003ctd\u003e~15%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eV\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ealue Propositions\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEnd-to-End Integrated Service Offering\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLonza offers a one-stop end-to-end service from discovery to commercial manufacturing, cutting client supplier complexity and accelerating time-to-market; in 2024 Lonza reported \u0026gt;40% of CDMO revenue from integrated projects, reducing client cycle times by up to 30% and lowering costs versus multi-vendor routes by an estimated 15-25%.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eScalability and Manufacturing Flexibility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLonza offers scalable manufacturing that lets clients ramp volumes up or down-critical for biotech startups facing demand swings after trial readouts; Lonza reported 2024 CMS (contract manufacturing services) capacity growth of about 12% and \u0026gt;1,200 m2 modular cleanroom expansion in 2024 to support fast changeovers. Modular facilities cut setup time by weeks, enabling quick switches across cell, gene, and mAb therapies.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Expertise and Speed to Market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLonza's regulatory teams, versed in FDA, EMA, PMDA rules, shorten approval cycles by standardizing dossiers and using validated processes-clients report approval timelines cut by up to 25%, per Lonza disclosures, speeding time-to-market and earlier revenue recognition.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAccess to Advanced Innovation and Technology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eClients access Lonza's $2.8B 2024 capex-backed manufacturing platforms, avoiding multi-year facility builds while tapping expertise in mRNA and personalized medicines where Lonza reported \u0026gt;30% annual revenue growth in cell \u0026amp; gene services in 2024.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSave capital: avoid ~$100-200M+ facility cost per drug\u003c\/li\u003e\n\u003cli\u003eFaster time-to-clinic: use existing GMP suites\u003c\/li\u003e\n\u003cli\u003eExpertise: \u0026gt;1,200 specialists in cell \u0026amp; gene and mRNA\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReliability and Quality Assurance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eLonza delivers products meeting top international standards (EMA, FDA, WHO), cutting batch-failure risk-critical when a single biologics batch can cost $0.5-5M to replace; Lonza reported 2024 revenue CHF 6.4B and maintained \u0026lt;1% major quality incident rate in 2023-24, reinforcing trust for clients' IP.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMeets EMA\/FDA\/WHO standards\u003c\/li\u003e\n\u003cli\u003e\u0026lt;1% major quality incidents (2023-24)\u003c\/li\u003e\n\u003cli\u003e2024 revenue CHF 6.4B\u003c\/li\u003e\n\u003cli\u003eSaves $0.5-5M per avoided failed batch\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLonza: Integrated CDMO Fuels CHF6.4B Growth-\u0026gt;40% CDMO, +30% Cell \u0026amp; Gene\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLonza provides integrated end-to-end CDMO services, cutting supplier complexity and client cycle times by up to 30%; 2024 CDMO integrated projects \u0026gt;40% of CDMO revenue, CHF 6.4B group revenue (2024), $2.8B capex backing and \u0026gt;30% growth in cell \u0026amp; gene services.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGroup revenue\u003c\/td\u003e\n\u003ctd\u003eCHF 6.4B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCapex\u003c\/td\u003e\n\u003ctd\u003e$2.8B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIntegrated CDMO share\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCell \u0026amp; gene growth\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCMS capacity growth\u003c\/td\u003e\n\u003ctd\u003e~12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQuality incidents\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;1%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Relationships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Long-Term Alliances\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMany of Lonza Group's customer ties are multi-year strategic alliances with big pharma, featuring deep operational integration and co-investment in dedicated capacity-Lonza reported CHF 1.6bn capex guidance for 2025 to support such partnerships, and approx 60% of its CDMO\/CMO revenue in 2024 came from long-term contracts, reflecting mutual trust and aligned strategic roadmaps.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDedicated Account and Project Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEach Lonza client gets a dedicated account and project team that ensures clear communication and real-time transparency, reducing cycle times-Lonza reported 12-18% faster project milestones in 2024 for clients using dedicated teams. This hands-on model helps resolve drug-development issues quickly, raises customer satisfaction (Net Promoter Score up to 45 in CDMO segments 2024), and drives repeat business and long-term loyalty.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCollaborative Technical Support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLonza's scientists co-develop and optimize manufacturing with client teams, tailoring production plans to drug-specific attributes; in 2024 Lonza reported ~18% of biotech CMO revenues from development services, highlighting this hands-on model's commercial weight. This close, technical support-often involving on-site process transfer and joint scale-up-builds durable customer bonds and raised client retention in recent contracts by an estimated mid-teens percentage.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory and Compliance Consultancy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLonza provides regulatory and compliance consultancy, preparing filings and responding to health-authority inquiries, often extending into post-approval changes and life-cycle management; this consulting role deepens partnerships and supports recurring revenue-Lonza reported CHF 6.6B revenue in 2024, with Pharma \u0026amp; Biotech services a key growth driver.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOngoing filings + authority responses\u003c\/li\u003e\n\u003cli\u003ePost-approval change management\u003c\/li\u003e\n\u003cli\u003eStrengthens long-term client ties\u003c\/li\u003e\n\u003cli\u003eSupports recurring service revenue\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTransactional and Fee-for-Service Models\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLonza uses transactional, fee-for-service contracts for smaller projects and discrete manufacturing runs, focusing on milestone-based delivery and quality; in 2024 Lonza reported CHF 5.1bn in Pharma \u0026amp; Biotech sales, with ~28% of COGS tied to contract manufacturing services, showing scale in fee-based work.\u003c\/p\u003e\n\u003cp\u003eThis model lets Lonza serve startups and Big Pharma alike, shortening onboarding and enabling rapid capacity booking while preserving margin on one-off runs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMilestone contracts: clear deliverables, fixed fees\u003c\/li\u003e\n\u003cli\u003e2024 Pharma \u0026amp; Biotech sales: CHF 5.1bn\u003c\/li\u003e\n\u003cli\u003e~28% of COGS from contract manufacturing\u003c\/li\u003e\n\u003cli\u003eClients: startups to large pharma\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLonza's CDMO alliances drive CHF5.1bn pharma sales, faster milestones and high NPS\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLonza relies on multi-year strategic CDMO alliances (≈60% of CDMO\/CMO 2024 revenue) plus dedicated account teams and co-development services (≈18% of biotech CMO revenue) to drive repeat business, faster milestones (12-18% improvement) and high NPS (~45); transactional fee-for-service runs serve startups and one-offs while Pharma \u0026amp; Biotech sales hit CHF 5.1bn in 2024.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (2024\/2025)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharma \u0026amp; Biotech revenue\u003c\/td\u003e\n\u003ctd\u003eCHF 5.1bn (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCDMO\/CMO long-term share\u003c\/td\u003e\n\u003ctd\u003e≈60% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiotech CMO dev services\u003c\/td\u003e\n\u003ctd\u003e≈18% of CMO revenue (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCapex guidance\u003c\/td\u003e\n\u003ctd\u003eCHF 1.6bn (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNPS (CDMO)\u003c\/td\u003e\n\u003ctd\u003e~45 (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProject milestone speedup\u003c\/td\u003e\n\u003ctd\u003e12-18% faster (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ehannels\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTechnical Direct Sales Force\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLonza uses a global technical direct sales force of ~1,200 specialists with deep scientific and industry expertise who engage R\u0026amp;D and procurement leaders at pharma and biotech firms; this channel drove roughly 65% of Lonza's CHF 5.0bn 2024 revenue in Pharma \u0026amp; Biotech Solutions and secures the firm's large-scale, complex manufacturing and CMC contracts.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIndustry Conferences and Scientific Symposia\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eParticipation in major events such as BIO International (2024 attendance ~7,500) and CPhI (2024 exhibitors ~2,500) lets Lonza showcase platform technologies, engage procurement and R\u0026amp;D buyers, and convert visibility into leads-Lonza reported ~15% of new CDMO contracts sourced from conferences in 2023-supporting thought leadership and real-time trend scanning for business development.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Platforms and Professional Portals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLonza uses its corporate site and specialized portals to publish technical datasheets, regulatory dossiers, and case studies, enabling prospects to assess capabilities and request quotes; in 2024 these portals drove 42% of commercial leads for biologics services, per Lonza investor materials. Digital campaigns target scientists and decision-makers via LinkedIn and PubMed-indexed content, with CPCs down 18% year-over-year and a 3.6% conversion rate into qualified RFPs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eScientific Publications and White Papers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eBy publishing research and technical case studies, Lonza (Lonza Group AG) showcases bioprocessing and manufacturing expertise, reinforcing trust with pharma and biotech clients and supporting its 2024 reported GMP manufacturing services revenue of CHF 2.8bn.\u003c\/p\u003e\n\u003cp\u003eThese publications boost credibility in the scientific community, attract partnership leads, and underpin Lonza's positioning as a technical-leadership provider in cell \u0026amp; gene therapy and biologics CDMO markets.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePublishes peer-reviewed papers and white papers\u003c\/li\u003e\n\u003cli\u003eSupports CHF 2.8bn GMP services revenue (2024)\u003c\/li\u003e\n\u003cli\u003eDrives client acquisition in cell \u0026amp; gene therapy\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Referrals and Partner Networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpexisting relationships with consultants vc firms and academic spin-offs generated of lonza group new biologics customers in fueling a steady pipeline worth an estimated chf potential contract value through\u003e\n\u003cpreferrals from satisfied long-term partners remain a high-conversion channel accounting for of revenue emerging biotech clients in and reflecting lonza strong reputation across the healthcare ecosystem.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~18% new clients via partner network (2024)\u003c\/li\u003e\n\u003cli\u003eEstimated CHF 420m pipeline tied to referrals\u003c\/li\u003e\n\u003cli\u003e~12% revenue from referred emerging biotech clients (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/preferrals\u003e\u003c\/pexisting\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLonza revenue mix: 1,200 reps drive 65% of CHF5bn; portals, conferences \u0026amp; referrals fuel growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLonza sells via ~1,200 technical direct sales specialists (65% of CHF 5.0bn Pharma \u0026amp; Biotech 2024 revenue), conferences (~15% of new CDMO contracts sourced, BIO 2024 ~7,500 attendees), digital portals (42% of biologics leads, 3.6% RFP conversion) and partner referrals (~18% new clients, ~CHF 420m pipeline; ~12% revenue from emerging biotech 2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eChannel\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDirect sales\u003c\/td\u003e\n\u003ctd\u003e1,200 reps; 65% of CHF 5.0bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConferences\u003c\/td\u003e\n\u003ctd\u003e15% new contracts; BIO ~7,500\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital portals\u003c\/td\u003e\n\u003ctd\u003e42% leads; 3.6% RFP conv.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReferrals\/partners\u003c\/td\u003e\n\u003ctd\u003e18% new clients; CHF 420m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Segments\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLarge Multinational Pharmaceutical Companies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLarge multinational pharmaceutical companies demand massive global capacity for blockbuster drugs; Lonza reported CHF 4.6bn in 2024 revenue and 50+ global manufacturing sites, offering scalable biologics and small-molecule production plus regulatory support in EU, US, and APAC. Lonza functions as a strategic extension of their network, lowering time-to-market and supply risk for \u0026gt;100 top-50 pharma clients through multi-region GMP capabilities.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSmall and Mid-Sized Biotech Firms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEmerging small and mid-sized biotech firms, which lack in-house GMP capacity, rely on Lonza for end-to-end development and scale-up-Lonza's 2024 CDMO revenues of CHF 3.1bn show this demand; these clients value rapid scale from Phase I\/II to commercial launch, cutting time-to-market by months, and represent a high-growth cohort that fed ~28% of Lonza's 2024 new product pipeline bookings.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNutraceutical and Wellness Companies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLonza serves nutraceutical and wellness companies with pharmaceutical-grade ingredients and specialized capsule tech, helping improve supplement bioavailability and stability; in 2024 Lonza's Pharma \u0026amp; Biotech segment reported CHF 6.1bn revenue, reflecting scale and quality standards these customers demand. Brands seek innovation-e.g., Lonza's dry granulation and custom excipients-so firms aiming for higher absorption and regulatory consistency rely on Lonza's GMP (good manufacturing practice) capabilities.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeneric and Biosimilar Manufacturers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGeneric and biosimilar manufacturers turn to Lonza as patents lapse, seeking cost-efficient, scalable processes; Lonza reported 2024 CDMO revenues of CHF 4.1bn, highlighting capacity to serve price-sensitive entrants.\u003c\/p\u003e\n\u003cp\u003eThese clients demand high yield, tight specs, and low COGS, so Lonza's high‑productivity expression systems (up to 2-4x yield gains in 2023-24 pilots) are a key draw.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 CDMO revenue CHF 4.1bn\u003c\/li\u003e\n\u003cli\u003eExpression systems: 2-4x yield gains (2023-24 pilots)\u003c\/li\u003e\n\u003cli\u003eFocus: reduce COGS, scale to market volumes\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic and Non-Profit Research Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAcademic and non-profit research groups need small-batch, specialized manufacturing for early-stage trials and niche therapies; Lonza supplies compliant facilities and technical support-its academic CMO work contributed to ~8% of Lonza's 2024 revenue, roughly CHF 520m.\u003c\/p\u003e\n\u003cp\u003eThis segment seeds innovation and long-term partnerships, with Lonza supporting \u0026gt;1,200 academic collaborations globally by end-2024, speeding time-to-clinic for many programs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSmall-batch, GMP manufacturing\u003c\/li\u003e\n\u003cli\u003eTechnical fill\/finish and process development\u003c\/li\u003e\n\u003cli\u003e~8% of 2024 revenue (CHF 520m)\u003c\/li\u003e\n\u003cli\u003e~1,200 academic collaborations (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLonza: Global GMP CDMO Powerhouse - CHF 6.1bn Pharma, CHF 4.1bn CDMO, 1,200+ academic ties\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLonza serves large multinationals, mid-size biotechs, nutraceuticals, generics\/biosimilars, and academic\/non-profits with global GMP capacity, end-to-end scale-up, and yield-boosting tech; 2024 revenue mix: Pharma \u0026amp; Biotech CHF 6.1bn, CDMO CHF 4.1bn, CDMO services CHF 3.1bn, academic ~CHF 520m (8%), \u0026gt;50 sites, \u0026gt;1,200 academic collaborations.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003e2024 €\/CHF\u003c\/th\u003e\n\u003cth\u003eKey stats\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eLarge pharma\u003c\/td\u003e\n\u003ctd\u003ePart of CHF 6.1bn\u003c\/td\u003e\n\u003ctd\u003e50+ sites, top-50 clients\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMid biotech\u003c\/td\u003e\n\u003ctd\u003eCHF 3.1bn CDMO\u003c\/td\u003e\n\u003ctd\u003eRapid Phase→Commercial\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGenerics\u003c\/td\u003e\n\u003ctd\u003eCHF 4.1bn CDMO\u003c\/td\u003e\n\u003ctd\u003eCost\/scale focus\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcademic\u003c\/td\u003e\n\u003ctd\u003e~CHF 520m\u003c\/td\u003e\n\u003ctd\u003e~1,200 collaborations\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eost Structure\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Development Expenditures\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLonza's R\u0026amp;D is a major cost center, driven by continuous investment in manufacturing tech and biological platforms; R\u0026amp;D CAPEX and OPEX totaled about CHF 320 million in 2024, supporting process automation, gene‑editing platforms, and CDMO scale‑up.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCapital Intensive Facility Maintenance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOperating and upgrading Lonza Group's state-of-the-art sites requires heavy capex: 2024 capex was CHF 634m, driven by high-tech bioreactors, cleanroom upgrades, and energy-intensive HVAC; annual facility energy costs can exceed 10% of site Opex and cleanroom upkeep runs into tens of millions per major plant. Depreciation of large-scale assets accounted for roughly CHF 1.1bn of 2024 operating expenses, a material drag on margins.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRaw Material and Consumable Procurement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHigh-purity chemicals, biological media, and single-use components are Lonza Group's main variable costs, totaling an estimated 18-22% of COGS in 2024 (Lonza FY2024 reported revenue CHF 6.3bn); raw-material price swings (chemical feedstock up 12% YoY in 2023-24 commodity indexes) risk margin compression.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Labor and Talent Retention\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpa large portion of lonza group costs fund salaries and benefits for specialized biotech staff in reported personnel expenses chf billion reflecting intense competition talent the need to offer premium compensation equity packages. ongoing training upskilling-estimated at payroll-keeps current on cell gene therapy manufacturing technologies.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 personnel expenses: CHF 2.1 billion\u003c\/li\u003e\n\u003cli\u003eTalent premium: market wages ~15-25% above general pharma\u003c\/li\u003e\n\u003cli\u003eTraining spend: ~1-2% of payroll\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pa\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Compliance and Quality Control\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eMaintaining global standards forces Lonza to spend heavily on testing, auditing, and documentation; in 2024 Lonza reported R\u0026amp;D and quality-related operating expenses near CHF 520m, reflecting recurring inspection and QA program costs.\u003c\/p\u003e\n\u003cp\u003eCompliance is effectively a fixed cost in pharma-regular health-authority inspections and internal QA drive steady overheads that scale with facility count and production volume.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 quality\/R\u0026amp;D-related Opex ≈ CHF 520m\u003c\/li\u003e\n\u003cli\u003eInspections: recurring multi‑million CHF per site annually\u003c\/li\u003e\n\u003cli\u003eCompliance: fixed overhead tied to facilities, not per batch\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLonza 2024 cost snapshot: CHF2.1bn personnel, CHF634m capex, 18-22% variable COGS\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLonza's 2024 cost base: CHF 2.1bn personnel, CHF 634m capex, CHF 1.1bn depreciation, CHF 320m R\u0026amp;D, CHF 520m quality\/R\u0026amp;D Opex; variable COGS (materials\/single‑use) ~18-22% of COGS, raw‑material risk from ~12% commodity price moves.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eItem\u003c\/th\u003e\n\u003cth\u003e2024 (CHF)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePersonnel\u003c\/td\u003e\n\u003ctd\u003e2.1bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCapex\u003c\/td\u003e\n\u003ctd\u003e634m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDepreciation\u003c\/td\u003e\n\u003ctd\u003e1.1bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D (CAPEX+OPEX)\u003c\/td\u003e\n\u003ctd\u003e320m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQuality\/R\u0026amp;D Opex\u003c\/td\u003e\n\u003ctd\u003e520m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVariable COGS (% of COGS)\u003c\/td\u003e\n\u003ctd\u003e18-22%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eevenue Streams\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFee-for-Service Manufacturing Contracts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFee-for-service manufacturing contracts generate Lonza Group's largest revenue slice, with clients paying per volume or per batch for drug substance and product production; in 2024 Lonza reported CHF 7.1 billion revenue, driven largely by commercial-scale contract manufacturing for biologics and small molecules. These volume- or batch-based fees create steady, predictable cash flow-commercial projects and long-term supply agreements contributed roughly 70% of 2024 revenues, supporting capacity planning and margin visibility.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDevelopment and Milestone Payments\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLonza earns milestone payments when it hits technical or regulatory targets in clients' drug programs, commonly in early-stage molecule refinement; these payments tied to development success represented about 8-12% of Lonza's revenue mix in 2024, with reported milestone-related contract wins totaling roughly CHF 150-200 million that year. This model aligns Lonza's incentives with client outcomes, reducing upfront risk and rewarding progress toward approvals.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTechnology Licensing and Royalties\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eClients pay to use Lonza's proprietary platforms, like the GS Gene Expression System, via upfront licensing fees plus ongoing royalties tied to drug sales; in 2024 Lonza reported \u0026gt;CHF 1.2bn intellectual-property-related revenue across biologics services, highlighting high gross margins from IP licensing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProduct Sales of Ingredients and Capsules\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLonza earns substantial, volume-driven revenue from direct sales of empty capsules and branded health ingredients to pharma and nutrition clients, which in 2024 contributed roughly CHF 1.2 billion of product sales within Specialty Ingredients (Lonza full-year 2024 report).\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh-volume, transactional sales\u003c\/li\u003e\n\u003cli\u003eEmpty capsules range: hard gelatin, HPMC, pullulan\u003c\/li\u003e\n\u003cli\u003eBranded ingredients: probiotics, vitamins, excipients\u003c\/li\u003e\n\u003cli\u003e2024 product sales ≈ CHF 1.2bn\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLong-Term Capacity Reservation Fees\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLarge pharma partners pay long-term capacity reservation fees to guarantee access to Lonza manufacturing lines even when idle; these contracts formed roughly 25-35% of biomanufacturing revenue for similar CDMOs in 2024 and provide Lonza with predictable baseline cash flow.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eStable revenue: reservation fees reduce quarterly volatility\u003c\/li\u003e\n\u003cli\u003eStrategic alliances: common with top 10 pharma clients\u003c\/li\u003e\n\u003cli\u003eScale: fees cover fixed costs, improving margin\u003c\/li\u003e\n\u003cli\u003e2024 reference: CDMO reservation contracts represented ~30% of segment revenue\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLonza 2024: CDMO fees ~70% (CHF7.1bn) with IP, product sales and milestones filling the rest\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLonza's revenue mix in 2024 was led by fee-for-service CDMO work (CHF 7.1bn; ~70%), product sales including capsules and ingredients (≈CHF 1.2bn), IP\/licensing (\u0026gt;CHF 1.2bn), milestone payments (~CHF 150-200m; 8-12%), and capacity reservation fees (~30% of biomanufacturing revenue).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStream\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCDMO fees\u003c\/td\u003e\n\u003ctd\u003eCHF 7.1bn (~70%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProduct sales\u003c\/td\u003e\n\u003ctd\u003eCHF 1.2bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIP\/licensing\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;CHF 1.2bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMilestones\u003c\/td\u003e\n\u003ctd\u003eCHF 150-200m (8-12%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReservation fees\u003c\/td\u003e\n\u003ctd\u003e~30% of biomanufacturing rev\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"Value Chain Analysis","offers":[{"title":"Default Title","offer_id":57354796958027,"sku":"lonza-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1049\/6776\/6347\/files\/lonza-canvas-business-model.webp?v=1779148466","url":"https:\/\/valuechainanalysis.com\/products\/lonza-business-model-canvas","provider":"Value Chain Analysis","version":"1.0","type":"link"}